NEU neuren pharmaceuticals limited

Because revenue growth for 2025 (relative to 2024) is priced...

  1. 2,524 Posts.
    lightbulb Created with Sketch. 690
    Because revenue growth for 2025 (relative to 2024) is priced totally in. Right now our $750m EV is just over 5 times last years NPAT we all know 2024 and 2023 had a higher amount of one offs, yet somehow that's a bad thing? We're victims of our own success I suppose.

    Guidance for licensing income alone (not including one offs) is $62-67m - a lot of which will go straight to bottom line given our measly overhead costs. That's barely over 10 forward PE for a high quality growing reoccuring income source not the mention the few hundred million dollars (in USD) milestones that could into play for both RoW and NA. R&D expense for Phase 3 is our main item but we have cash at bank to handle that and we know (if succesful) that the money invested there will make the company worth 5x more at least.

    You may be able to sell and buy back cheaper but that's entirely dependent on more people panic selling and you buying back in again.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.54
Change
0.100(0.80%)
Mkt cap ! $1.559B
Open High Low Value Volume
$12.44 $12.73 $12.13 $11.07M 885.6K

Buyers (Bids)

No. Vol. Price($)
1 1215 $12.52
 

Sellers (Offers)

Price($) Vol. No.
$12.54 804 1
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.